- Correction
- Open Access
- Published:
Correction to: Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents Iris
Journal of Nanobiotechnology volume 20, Article number: 229 (2022)
The Original Article was published on 02 February 2022
Correction to: Journal of Nanobiotechnology (2022) 20:64 https://doi.org/10.1186/s12951-022-01272-5
Following publication of the original article [1], the authors identified an error in Fig. 1 and Fig. 4. The correct figures are given in this correction article.
The error was in the “R-groups” (R1 and R2) of the molecules IH18 and IH20 in Fig. 1b and in Additional file 1: Figure S1. R1 and R2 were accidently swapped. In Fig. 4d the error was in the depiction of the tumor/blood ratio. During transfer of the data to this bar graph the data got unintentionally transformed.
Molecular toolbox of site-specific functionalizable anti-PD-L1 antibody formats and imaging peptides. A Application of the CRISPR/HDR strategy to anti-PD-L1 hybridoma MIH5 created a sortaggable Fab fragment and chimeric mouse IgG1 monoclonal antibody against PD-L1. B Molecular structure of imaging peptides IH20 and IH18
Biodistribution results of anti-PD-L1 multimodal imaging tools. Biodistribution is shown at several time points after injection (p.i.) of 111In-labeled A mIgG1-IH18, B Fab-IH18 or C Fab-IH18-PEG. D Tumor uptake values (left graph) and tumor/blood ratios (right graph) of the three constructs are compared directly at each time point. Data are shown as mean ± SD, n = 5
Reference
Hagemans M, Wierstra PJ, Steuten K, MolkenboerKuenen JDM, Dalen D, Beest M, Schoot JMS, Ilina O, Gotthardt M, Figdor CG, Scheeren FA, Heskamp S, Verdoes M. Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defned imaging agents Iris. J Nanobiotechnol. 2022;20:64. https://doi.org/10.1186/s12951-022-01272-5.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original article has been revised.
Supplementary Information
Additional file 1.
Supplementary figures and tables.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Hagemans, I.M., Wierstra, P.J., Steuten, K. et al. Correction to: Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents Iris. J Nanobiotechnol 20, 229 (2022). https://doi.org/10.1186/s12951-022-01306-y
Published:
DOI: https://doi.org/10.1186/s12951-022-01306-y